Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1406 - Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult Leukemia Group

    Primary Author / Presenter(s)

  • KZ

    Klaudia Zielonka, MD

    Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw
    Warsaw, Mazowieckie, Poland

    • Co-Author(s)

  • BI

    Blazej Izdebski, MD

    Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw
    Warsaw, Mazowieckie, Poland

  • JD

    Joanna E. Drozd-Sokolowska, MD, PhD

    assistant professor
    Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw
    Warsaw, Mazowieckie, Poland

  • KP

    Katarzyna Pruszczyk, MD, PhD

    Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
    Warsaw, Mazowieckie, Poland

  • BP

    Bartosz Pula, MD, PhD

    Hematologist
    Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital
    Łódź, Lodzkie, Poland

  • KW

    Kamil Wisniewski, MD, PhD

    Department of Hematology, Instutute of Hematology and Transfusion Medicine
    Warsaw, Mazowieckie, Poland

  • WS

    Waldemar Sawicki, MD, PhD

    Department of Internal Medicine and Hematology, Military Institute of Medicine-National Research Institute
    Warsaw, Mazowieckie, Poland

  • EK

    Elzbieta Kalicinska, MD, PhD

    Assistant
    Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University
    Wroclaw, Dolnoslaskie, Poland

  • PJ

    Paula Jablonowska-Babij, MSc

    Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University
    Wroclaw, Dolnoslaskie, Poland

  • AB

    Aleksandra Butrym, MD, PhD

    Department of Cancer Prevention and Therapy, Wroclaw Medical University; Alfred Sokolowski Specialist Hospital in Walbrzych Oncology Support Centre for Clinical Trials
    Walbrzych, Dolnoslaskie, Poland

  • TB

    Tomasz Buczek, MPharm

    Alfred Sokolowski Specialist Hospital in Walbrzych Oncology Support Centre for Clinical Trials; Department of Clinical Pharmacology, Wroclaw Medical University
    Wałbrzych, Dolnoslaskie, Poland

  • ES

    Edyta Subocz, MD

    Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Department of Hematology, Internal Medicine and BMT
    Olsztyn, Warminsko-Mazurskie, Poland

  • JH

    Janusz Halka, MD, PhD

    Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Department of Hematology and BMT; University of Warmia and Mazury in Olsztyn
    Olsztyn, Warminsko-Mazurskie, Poland

  • MW

    Magdalena Witkowska, MD, PhD

    Department of Hematology, Medical University of Lodz
    Lodz, Lodzkie, Poland

  • MW

    Mateusz Wilk, MD

    Haematology and Internal Medicine Clinical Department, University Hospital Kraków
    Cracow, Malopolskie, Poland

  • MH

    Maria Hryniewiecka, MD

    Department of Hematology and Bone Marrow Transplantation, Polish Red Cross Maritime Hospital
    Gdynia, Pomorskie, Poland

  • KG

    Karolina Gruenpeter, MD

    Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia
    Katowice, Slaskie, Poland

  • EC

    Edyta Cichocka, MD, PhD

    Department of Haematology, Rydygiera Hospital in Torun
    Torun, Kujawsko-Pomorskie, Poland

  • PH

    Piotr Halicki, MD

    Department of Haematology, Medical University of Bialystok
    Bialystok, Podlaskie, Poland

  • KW

    Kamil Wdowiak, MD

    Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia
    Katowice, Slaskie, Poland

  • EI

    Elżbieta Iskierka-Jażdżewska, MD, PhD

    Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital in Lodz, Poland
    Łódź, Lodzkie, Poland

  • AK

    Anna Kopinska, MD

    Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia
    Katowice, Slaskie, Poland

  • AS

    Anastazja Szlauer-Stefanska, MD, PhD

    Bone Marrow Transplantation and Oncohematology Department, Maria Sklodowska-Curie National Research Institute of Oncology (branch in Gliwice),
    Gliwice, Slaskie, Poland

  • AS

    Agnieszka Szymczyk, MD, PhD

    Department of Hematology, National Institute of Medicine of the Ministry of the Interior and Administration
    Warsaw, Mazowieckie, Poland

  • AW

    Anna Wolska-Washer, MD, PhD

    Department of Hematology, Medical University of Lodz
    Lodz, Lodzkie, Poland

  • JK

    Jolanta Kowalczyk, MD, PhD

    Department of Hematology, Transplantation and Internal Medicine, University Clinical Center of the Medical University of Warsaw
    Warsaw, Mazowieckie, Poland

  • TW

    Tomasz Wrobel, MD, PhD

    Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University
    Wroclaw, Dolnoslaskie, Poland

  • IH

    Iwona Hus, MD, PhD

    Professor
    National Medical Institute of the Ministry of the Interior and Administration
    Warsaw, Poland

  • KJ

    Krzysztof Jamroziak, MD, PhD

    Professor, Deputy Head of the Department of Hematology
    Medical University of Warsaw
    Warsaw, Poland